SMS Pharmaceuticals Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/x9oeh5u65mbiecqui25bb1kt.pdf

Key Takeaways


The ARV Reset

Potluri: "That we cannot guarantee, but definitely as I said slow process, it will take some time, but at this point of time we cannot comment on that, because it is tender. We do not know who will be awarded the tender and there is lot of ambiguity about who will get the tender and things like that."

The Diversification That Saved the Year


Margin Recovery Path

Potluri: "Yes definitely, it will not happen overnight, it is a gradual process obviously because of COVID, lot of stocks being high for the customers and lack of demand from the customer side. ... over next one to two years, I think it is definitely possibility of going back to 20% EBITDA margin."

Ibuprofen: Volume Ramp, Price Risk

Potluri: "we cannot predict but there could be a couple of months where there could be some shortage or any issues with any other suppliers then suddenly it could be a good month where Ibuprofen prices could reach $12 or $13 and again could come back to again $10, so it is a cycle that happens typically."

Capacity, Capex & Consolidation

Potluri: "We have no plans to undertake any Greenfield or Brownfield projects at this point of time. As a company we would like to consolidate before our next project at this point of time."

R&D and the Next Leg


Guidance & Commitments

CommitmentSpecificsTimeline
Topline growthAt least 20% YoY growth vs FY23FY24 full year
EBITDA marginIncrease by 250–300 bps from ~15% base; blended target close to 17%FY24 full year
ARV contributionReturn to around 20% of revenue, with decent contribution startingNext couple of quarters
Ibuprofen scaleReach ~700 tons per monthNext six months
Capacity utilizationReach 75–80% before any Greenfield decisionFY24
Pre-COVID marginsReturn to 20% EBITDA marginNext one to two years (gradual)
Major capexNo Greenfield/Brownfield; only maintenance capexFY24; possible capex in FY25 based on performance
CDMO entryMove into CDMO spaceNext couple of years

Key Metrics

MetricQ4 FY23
Revenue₹149 Crores
API segment revenue₹146.1 Crores, 97.8% of consolidated revenue
PAT₹8 Crores, +53% QoQ
EBITDA margin16.4%, +246 bps QoQ
API domestic market share15% of API revenue; export 85%
API therapeutic mix: anti-diabetic26% of API revenue
API therapeutic mix: anti-migraine21% of API revenue
API therapeutic mix: anti-inflammatory17% of API revenue
API therapeutic mix: anti-ulcer13% of API revenue
API therapeutic mix: anti-ED function8% of API revenue
API therapeutic mix: anti-epileptic3% of API revenue
ARV segment contributionAlmost negligible
Capacity utilization~65% to 70%
Ibuprofen commercial operation300 metric tons
FY2024 topline growth guidanceAt least 20% vs FY2023
FY2024 EBITDA margin guidanceClose to 17%